Tackling virological failure in HIV-infected children living in Africa

References

• World health organization. HIV/AIDS Fact sheet N°360, 2014. Available from: www.who.int/mediacentre/factsheets/fs360/en/ [Last accessed 15 January 2015]
   Google Scholar
• Becquet R, Marston M, Dabis F, et al. Children who acquire HIV infection perinatally are at higher risk of early death than those acquiring infection through breast milk: a meta-analysis. PLoS One 2012;7(2):e28510
   PubMed Web of Science ®Google Scholar
• United nations program on HIV and AIDS. Progress report on the global plan: Joint United Nations Programme on HIV/AIDS Geneva, Switzerland; 2013
   Google Scholar
• World Health Organization. GLOBAL HIV/AIDS RESPONSE: Epidemic update and health sector progress towards universal access. Geneva, Switzerland; 2013
   Google Scholar
• World Health Organization. Manual on paediatric HIV care and treatment for district hospitals. Geneva, Switzerland; 2011
   Google Scholar
• Foster C, Judd A, Tookey P, et al. Young people in the United Kingdom and Ireland with perinatally acquired HIV: the pediatric legacy for adult services. AIDS Patient Care STDS 2009;23(3):159-66
   PubMed Web of Science ®Google Scholar
• Castro H, Judd A, Gibb DM, et al. Risk of triple-class virological failure in children with HIV: a retrospective cohort study. Lancet 2011;377(9777):1580-7
   PubMed Web of Science ®Google Scholar
• Fassinou P, Elenga N, Rouet F, et al. Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Cote d’Ivoire. AIDS 2004;18(14):1905-13
   PubMed Web of Science ®Google Scholar
• Reddi A, Leeper SC, Grobler AC, et al. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa. BMC Pediatr 2007;7:13
   PubMedGoogle Scholar
• Emmett SD, Cunningham CK, Mmbaga BT, et al. Predicting virologic failure among HIV-1-infected children receiving antiretroviral therapy in Tanzania: a cross-sectional study. J Acquir Immune Defic Syndr 2010;54(4):368-75
   PubMed Web of Science ®Google Scholar
• Technau KG, Lazarus K, Kuhn L, et al. Poor early virologic performance and durability of abacavir-based first-line regimens for HIV-infected children. Pediatr Infect Dis J 2013;32(8):851-5
   PubMed Web of Science ®Google Scholar
• Pubmed.gov, US National Library of Medicine National Institutes of Health. Available from: www.ncbi.nlm.nih.gov/pubmed/
   Google Scholar
• Arrive E, Dicko F, Amghar H, et al. HIV status disclosure and retention in care in HIV-infected adolescents on antiretroviral therapy (ART) in West Africa. PLoS One 2012;7(3):e33690
   PubMed Web of Science ®Google Scholar
• Zoufaly A, Fillekes Q, Hammeri R, et al. Prevalence and determinants of virological failure in HIV-infected children on antiretroviral therapy in rural Cameroon: a cross-sectional study. Antivir Ther 2013;18(5):681-90
   PubMed Web of Science ®Google Scholar
• Shah CA. Adherence to high activity antiretrovial therapy (HAART) in pediatric patients infected with HIV: issues and interventions. Indian J Pediatr 2007;74(1):55-60
   PubMed Web of Science ®Google Scholar
• Sebunya R, Musiime V, Kitaka SB, et al. Incidence and risk factors for first line anti retroviral treatment failure among Ugandan children attending an urban HIV clinic. AIDS Res Ther 2013;10(1):25
   PubMedGoogle Scholar
• Bacha T, Tilahun B, Worku A. Predictors of treatment failure and time to detection and switching in HIV-infected Ethiopian children receiving first line anti-retroviral therapy. BMC Infect Dis 2012;12:197
   PubMed Web of Science ®Google Scholar
• Haberer JE, Cook A, Walker AS, et al. Excellent adherence to antiretrovirals in HIV+ Zambian children is compromised by disrupted routine, HIV nondisclosure, and paradoxical income effects. PLoS One 2011;6(4):e18505
   PubMed Web of Science ®Google Scholar
• Biadgilign S, Deribew A, Amberbir A, et al. Adherence to highly active antiretroviral therapy and its correlates among HIV infected pediatric patients in Ethiopia. BMC Pediatr 2008;8:53
   PubMed Web of Science ®Google Scholar
• Lowenthal E, Lawler K, Harari N, et al. Rapid psychosocial function screening test identified treatment failure in HIV+ African youth. AIDS Care 2012;24(6):722-7
   PubMed Web of Science ®Google Scholar
• Barry O, Powell J, Renner J, et al. Effectiveness of first-line antiretroviral therapy and correlates of longitudinal changes in CD4 and viral load among HIV-infected children in ghana. BMC Infect Dis 2013;13:476
   PubMed Web of Science ®Google Scholar
• Kekitiinwa A, Asiimwe AR, Kasirye P, et al. Prospective long-term outcomes of a cohort of ugandan children with laboratory monitoring during antiretroviral therapy. Pediatr Infect Dis J 2012;31(8):e117-25
   PubMed Web of Science ®Google Scholar
• MacLeod IJ, Rowley CF, Thior I, et al. Minor resistant variants in nevirapine-exposed infants may predict virologic failure on nevirapine-containing ART. J Clin Virol 2010;48(3):162-7
   PubMed Web of Science ®Google Scholar
• Ruel TD, Kakuru A, Ikilezi G, et al. Virologic and immunologic outcomes of HIV-infected Ugandan children randomized to lopinavir/ritonavir or nonnucleoside reverse transcriptase inhibitor therapy. J Acquir Immune Defic Syndr 2014;65(5):535-41
   PubMed Web of Science ®Google Scholar
• Chohan BH, Tapia K, Merkel M, et al. Pooled HIV-1 RNA viral load testing for detection of antiretroviral treatment failure in Kenyan children. J Acquir Immune Defic Syndr 2013;63(3):e87-93
   PubMed Web of Science ®Google Scholar
• May S, Gamst A, Haubrich R, et al. Pooled nucleic acid testing to identify antiretroviral treatment failure during HIV infection. J Acquir Immune Defic Syndr 2010;53(2):194-201
   PubMed Web of Science ®Google Scholar
• Barlow-Mosha L, Mudilpe P, Massavon W, et al. Validation of WHO 2010 immunologic criteria in predicting pediatric first-line antiretroviral treatment (ART) failure in ART- experienced children in Uganda: CD4 is a poor surrogate for virologic monitoring of pediatric ART failure [Abstract no. THPE062]. 19th International AIDS Conference; 22 – 27 Jul 2012; Washington DC, USA
   Google Scholar
• Romanelli RM, Pinto JA, Melo LJ, et al. Effectiveness of dual and triple antiretroviral therapy in the treatment of HIV-infected children. J Pediatr (Rio J) 2006;82(4):260-5
   PubMedGoogle Scholar
• Kamya MR, Mayanja-Kizza H, Kambugu A, et al. Predictors of long-term viral failure among Ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr 2007;46(2):187-93
   PubMed Web of Science ®Google Scholar
• Mutwa PR, Boer KR, Rusine J, et al. Long-term effectiveness of combination antiretroviral therapy and prevalence of HIV drug resistance in HIV-1-infected children and adolescents in Rwanda. Pediatr Infect Dis J 2014;33(1):63-9
   PubMed Web of Science ®Google Scholar
• Ford N, Meintjes G, Pozniak A, et al. The future role of CD4 cell count for monitoring antiretroviral therapy. Lancet Infect Dis 2015;15(2):241-7
   PubMed Web of Science ®Google Scholar
• Ndondoki C, Dicko F, Ahuatchi Coffie P, et al. Antiretroviral treatment response of HIV-infected children after prevention of mother-to-child transmission in West Africa. J Int AIDS Soc 2014;17:18737
   PubMedGoogle Scholar
• Woldesenbet SA, Jackson D, Goga AE, et al. Missed opportunities for early infant HIV diagnosis: results of a national study in South Africa. J Acquir Immune Defic Syndr 2015;68(3):e26-32
   PubMed Web of Science ®Google Scholar
• United Nations Program on HIV and AIDS. A progress report on the global plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive. Available from: www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2012/JC2385_ProgressReportGlobalPlan_en.pdf [ Last accessed 15 January 2015
   Google Scholar
• Lilian RR, Johnson LF, Moolla H, et al. A mathematical model evaluating the timing of early diagnostic testing in HIV-exposed infants in South Africa. J Acquir Immune Defic Syndr 2014;67(3):341-8
   PubMed Web of Science ®Google Scholar
• Mitchell C, Dross S, Beck IA, et al. Low concentrations of HIV-1 DNA at birth delays diagnosis, complicating identification of infants for antiretroviral therapy to potentially prevent the establishment of viral reservoirs. Clin Infect Dis 2014;58(8):1190-3
   PubMed Web of Science ®Google Scholar
• Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008;359(21):2233-44
   PubMed Web of Science ®Google Scholar
• Koller M, Patel K, Chi BH, et al. Immunodeficiency in children starting antiretroviral therapy in low-, middle-, and high-income countries. J Acquir Immune Defic Syndr 2015;68(1):62-72
   PubMed Web of Science ®Google Scholar
• Doherty T, Ngandu N, Blume J, et al. Early initiation of antiretroviral therapy amongst young children: a long way to go. J Acquir Immune Defic Syndr 2015. [Epub ahead of print]
   Google Scholar
• Cotton MF, Violari A, Otwombe K, et al. Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial. Lancet 2013;382(9904):1555-63
   PubMed Web of Science ®Google Scholar
• Puthanakit T, Saphonn V, Ananworanich J, et al. Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre, randomised, open-label trial. Lancet Infect Dis 2012;12(12):933-41
   PubMed Web of Science ®Google Scholar
• Collins IJ, Judd A, Gibb DM. Immediate antiretroviral therapy in young HIV-infected children: benefits and risks. Curr Opin HIV AIDS 2014;9(1):87-94
   PubMed Web of Science ®Google Scholar
• Laughton B, Cornell M, Grove D, et al. Early antiretroviral therapy improves neurodevelopmental outcomes in infants. AIDS 2012;26(13):1685-90
   PubMed Web of Science ®Google Scholar
• Puthanakit T, Ananworanich J, Vonthanak S, et al. Cognitive function and neurodevelopmental outcomes in HIV-infected Children older than 1 year of age randomized to early versus deferred antiretroviral therapy: the PREDICT neurodevelopmental study. Pediatr Infect Dis J 2013;32(5):501-8
   PubMed Web of Science ®Google Scholar
• World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach 2013. Available from: www.who.int/hiv/pub/guidelines/arv2013/en/index.html [Last accessed 15 January 2015]
   Google Scholar
• Prendergast A, Mphatswe W, Tudor-Williams G, et al. Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants. AIDS 2008;22(11):1333-43
   PubMed Web of Science ®Google Scholar
• Pillay V, Pillary C, Kantor R, et al. HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy. AIDS Res Hum Retroviruses 2008;24(11):1449-54
   PubMed Web of Science ®Google Scholar
• Zanoni BC, Sunpath H, Feeney ME. Pediatric response to second-line antiretroviral therapy in South Africa. PLoS One 2012;7(11):e49591
   PubMed Web of Science ®Google Scholar
• Kekitiinwa A, Cook A, Nathoo K, et al. Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial. Lancet 2013;381(9875):1391-403
   PubMed Web of Science ®Google Scholar
• World Health Organization. Antiretroviral therapy for HIV infection in infants and children: towards universal access recommendations for a public health approach. Geneva. 2010. Available from: www.who.int/hiv/pub/paediatric/infants2010/en/index.html [Last accessed 15 January 2015]
   Google Scholar
• Jeena PM, Pillay P, Pillay T, et al. Impact of HIV-1 co-infection on presentation and hospital-related mortality in children with culture proven pulmonary tuberculosis in Durban, South Africa. Int J Tuberc Lung Dis 2002;6(8):672-8
   PubMed Web of Science ®Google Scholar
• Lawn SD, Bekker LG, Middelkoop K, et al. Impact of HIV infection on the epidemiology of tuberculosis in a peri-urban community in South Africa: the need for age-specific interventions. Clin Infect Dis 2006;42(7):1040-7
   PubMed Web of Science ®Google Scholar
• Chintu C, Mwaba P. Tuberculosis in children with human immunodeficiency virus infection. Int J Tuberc Lung Dis 2005;9(5):477-84
   PubMed Web of Science ®Google Scholar
• Palme IB, Gudetta B, Degefu H, et al. Risk factors for human immunodeficiency virus infection in Ethiopian children with tuberculosis. Pediatr Infect Dis J 2001;20(11):1066-72
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Fromm MF, et al. Pharmacokinetic interactions with rifampicin : clinical relevance. Clin Pharmacokinet 2003;42(9):819-50
   PubMed Web of Science ®Google Scholar
• Zhang C, Denti P, Decloedt EH, et al. Model-based evaluation of the pharmacokinetic differences between adults and children for lopinavir and ritonavir in combination with rifampicin. Br J Clin Pharmacol 2013;76(5):741-51
   PubMed Web of Science ®Google Scholar
• Zhang C, McIlleron H, Ren Y, et al. Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children. Antivir Ther 2012;17(1):25-33
   PubMed Web of Science ®Google Scholar
• Reitz C, Coovadia A, Ko S, et al. Initial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis. J Infect Dis 2010;201(8):1121-31
   PubMed Web of Science ®Google Scholar
• Elsherbiny D, Ren Y, McIlleron H, et al. Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children. Eur J Clin Pharmacol 2010;66(10):1017-23
   PubMed Web of Science ®Google Scholar
• Frohoff C, Moodley M, Fairlie L, et al. Antiretroviral therapy outcomes in HIV-infected children after adjusting protease inhibitor dosing during tuberculosis treatment. PLoS One 2011;6(2):e17273
   PubMed Web of Science ®Google Scholar
• Hiruy H, Rogers Z, Mbowane C, et al. Subtherapeutic concentrations of first-line anti-TB drugs in South African children treated according to current guidelines: the PHATISA study. J Antimicrob Chemother 2015;70(4):1115-23
   PubMed Web of Science ®Google Scholar
• Dheda K, Gumbo T, Ghandi RN, et al. Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis. Lancet Respir Med 2014;2(4):321-38
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Guidelines for an integrated approach to the nutritional care of HIV-infected children (6 months-14 years): handbook, chart booklet and children for country adaption. Geneva. 2009
   Google Scholar
• United Nations Children’s Fund, World Health Organization World Bank. UNICEF-WHO-World Bank joint child malnutrition estimates. New York, USA/Geneva, Switzerland/Washington DC, USA. 2012
   Google Scholar
• Anabwani G, Navario P. Nutrition and HIV/AIDS in Sub-Saharan Africa: an overview. Nutrition 2005;21(1):96-9
   PubMed Web of Science ®Google Scholar
• Kruger HS, Balk LJ, Viljoen M, et al. Positive association between dietary iron intake and iron status in HIV-infected children in Johannesburg, South Africa. Nutr Res 2013;33(1):50-8
   PubMed Web of Science ®Google Scholar
• Prendergast A, Bwakura-Dangarembizi MF, Cook AD, et al. Hospitalization for severe malnutrition among HIV-infected children starting antiretroviral therapy. AIDS 2011;25(7):951-6
   PubMed Web of Science ®Google Scholar
• Jesson J, Leroy V. Challenges of malnutrition care among HIV-infected children on antiretroviral treatment in Africa. Med Mal Infect 2015;45(5):149-56
   PubMed Web of Science ®Google Scholar
• Sudfeld CR, Duggan C, Aboud S, et al. Vitamin D status is associated with mortality, morbidity, and growth failure among a prospective cohort of HIV-infected and HIV-exposed Tanzanian infants. J Nutr 2015;145(1):121-7
   PubMed Web of Science ®Google Scholar
• Zanoni BC, Phungula T, Zanoni HM, et al. Predictors of poor CD4 and weight recovery in HIV-infected children initiating ART in South Africa. PLoS One 2012;7(3):e33611
   PubMed Web of Science ®Google Scholar
• Babiker A, Castro nee Green H, Compagnucci A, et al. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. Lancet Infect Dis 2011;11(4):273-83
   PubMed Web of Science ®Google Scholar
• Hazra R, Gafni RI, Maldarelli F, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. Pediatrics 2005;116(6):e846-54
   PubMed Web of Science ®Google Scholar
• Gafni RI, Hazra R, Reynolds JC, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics 2006;118(3):e711-18
   PubMed Web of Science ®Google Scholar
• Purdy JB, Gafni RI, Reynolds JC, et al. Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J Pediatr 2008;152(4):582-4
   PubMed Web of Science ®Google Scholar
• Aurpibul L, Puthanakit T. Review of tenofovir use in HIV-infected children. Pediatr Infect Dis J 2015;34(4):383-91
   PubMed Web of Science ®Google Scholar
• Stohr W, Reid A, Walker AS, et al. Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa. Antivir Ther 2011;16(7):1011-20
   PubMed Web of Science ®Google Scholar
• Guidelines on the use of antiretroviral agents in pediatric HIV infection. United States National Government Guidelines. W., DC; 2015. Available from: http://aidsinfo.nih.gov/guidelines [Last accessed 5 June 2015]
   Google Scholar
• Dobroszycki J, Abadi J, Wiznia AA, et al. Profile of darunavir in the treatment of HIV-infected pediatric and adolescent patients. Adolesc Health Med Ther 2011;2:85-93
   PubMedGoogle Scholar
• Neely M, and Kovacs A, Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir. Ther Clin Risk Manag 2009;5(3):595-615
   PubMedGoogle Scholar
• Davies MA, Moultrie H, Eley B, et al. Virologic failure and second-line antiretroviral therapy in children in South Africa–the IeDEA Southern Africa collaboration. J Acquir Immune Defic Syndr 2011;56(3):270-8
   PubMed Web of Science ®Google Scholar
• Bock P, Boulle A, White C, et al. Provision of antiretroviral therapy to children within the public sector of South Africa. Trans R Soc Trop Med Hyg 2008;102(9):905-11
   PubMed Web of Science ®Google Scholar
• Zanoni BC, Phungula T, Zanoni HM, et al. Impact of tuberculosis cotreatment on viral suppression rates among HIV-positive children initiating HAART. AIDS 2011;25(1):49-55
   PubMed Web of Science ®Google Scholar
• Davies MA, Boulle A, White C, et al. Accuracy of immunological criteria for identifying virological failure in children on antiretroviral therapy - the IeDEA Southern Africa Collaboration. Trop Med Int Health 2011;16(11):1367-71
   PubMed Web of Science ®Google Scholar
• Ruel TD, Kamya MR, Li P, et al. Early virologic failure and the development of antiretroviral drug resistance mutations in HIV-infected Ugandan children. J Acquir Immune Defic Syndr 2011;56(1):44-50
   PubMed Web of Science ®Google Scholar
• Paediatric European Network for Treatment of AIDS. Response to planned treatment interruptions in HIV infection varies across childhood. AIDS 2010;24(2):231-41
   PubMed Web of Science ®Google Scholar
• Bunupuradah T, Duong T, Compagnucci A, et al. Outcomes after reinitiating antiretroviral therapy in children randomized to planned treatment interruptions. AIDS 2013;27(4):579-89
   PubMed Web of Science ®Google Scholar
• Li JZ, Smith DM, Mellors JW, The critical roles of treatment interruption studies and biomarker identification in the search for an HIV cure. AIDS 2015. [ Epub ahead of print
   Google Scholar
• Rutherford GW, Anglemyer A, Easterbrook PJ, et al. Predicting treatment failure in adults and children on antiretroviral therapy: a systematic review of the performance characteristics of the 2010 WHO immunologic and clinical criteria for virologic failure. AIDS 2014;28(2):S161-9
   PubMed Web of Science ®Google Scholar
• Workneh N, Girma T, Woldie M. Immunologic and clinical outcomes of children on HAART: a Retrospective cohort analysis at Jimma University specialized hospital. Ethiop J Health Sci 2009;19(2):75-82
   Google Scholar
• World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: towards universal access 2010. Available from: http://whqlibdoc.who.int/publications/2010/9789241599818_eng.pdf [Last accessed 12 January 2015]
   Google Scholar
• Casado JL, Hertogs K, Ruiz L, et al. Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen. AIDS 2000;14(2):F1-7
   PubMed Web of Science ®Google Scholar
• Conway B, Wainberg MA, Hall D, et al. Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine. AIDS 2001;15(10):1269-74
   PubMed Web of Science ®Google Scholar
• Deshpande A, Jauvin V, Magnin N, et al. Resistance mutations in subtype C HIV type 1 isolates from Indian patients of Mumbai receiving NRTIs plus NNRTIs and experiencing a treatment failure: resistance to AR. AIDS Res Hum Retroviruses 2007;23(2):335-40
   PubMed Web of Science ®Google Scholar
• Gordon M, Graham N, Bland R, et al. Surveillance of resistance in KZN South Africa, including mother-infant pairs 6 weeks after single-dose NVP. Antivir Ther 2004;9:S80
   Google Scholar
• Eshleman SH, Hoover DR, Chen S, et al. Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. AIDS 2005;19(18):2167-9
   PubMed Web of Science ®Google Scholar
• Arrive E, Newell ML, Ekouevi DK, et al. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol 2007;36(5):1009-21
   PubMed Web of Science ®Google Scholar
• Kebe K, Belec L, Diop Ndiaye H, et al. The case for addressing primary resistance mutations to non-nucleoside reverse transcriptase inhibitors to treat children born from mothers living with HIV in sub-Saharan Africa. J Int AIDS Soc 2014;17:18526
   PubMedGoogle Scholar
• Green TN, Archary M, Gordon ML, et al. Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in South Africa. AIDS Res Hum Retroviruses 2012;28(4):324-32
   PubMed Web of Science ®Google Scholar
• Fokam J, Salpini R, Santoro MM, et al. Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon. Pediatr Infect Dis J 2011;30(12):1062-8
   PubMed Web of Science ®Google Scholar
• Musiime V, Kaudha E, Kayiwa J, et al. Antiretroviral drug resistance profiles and response to second-line therapy among HIV type 1-infected Ugandan children. AIDS Res Hum Retroviruses 2013;29(3):449-55
   PubMed Web of Science ®Google Scholar
• Sigaloff KC, Kayiwa J, Musiime V, et al. Short communication: high rates of thymidine analogue mutations and dual-class resistance among HIV-infected Ugandan children failing first-line antiretroviral therapy. AIDS Res Hum Retroviruses 2013;29(6):925-30
   PubMed Web of Science ®Google Scholar
• Charpentier C, Gody JC, Mbitikon O, et al. Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: a cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. AIDS Res Hum Retroviruses 2012;28(1):87-94
   PubMed Web of Science ®Google Scholar
• Wamalwa DC, Lehman DA, Benki-Nugent S, et al. Long-term virologic response and genotypic resistance mutations in HIV-1 infected Kenyan children on combination antiretroviral therapy. J Acquir Immune Defic Syndr 2013;62(3):267-74
   PubMed Web of Science ®Google Scholar
• Gupta RK, Ford D, Mulenga V, et al. Drug resistance in human immunodeficiency virus type-1 infected Zambian children using adult fixed dose combination stavudine, lamivudine, and nevirapine. Pediatr Infect Dis J 2010;29(8):e57-62
   PubMed Web of Science ®Google Scholar
• Moultrie H, McIlleron H, Sawry S, et al. Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir. J Antimicrob Chemother 2015;70(2):543-9
   PubMed Web of Science ®Google Scholar
• Lankowski AJ, Siedner MJ, Bangsberg DR, et al. Impact of geographic and transportation-related barriers on HIV outcomes in sub-Saharan Africa: a systematic review. AIDS Behav 2014;18(7):1199-223
   PubMed Web of Science ®Google Scholar
• Gebremedhin A, Gebremariam S, Haile F, et al. Predictors of mortality among HIV infected children on anti-retroviral therapy in Mekelle Hospital, Northern Ethiopia: a retrospective cohort study. BMC Public Health 2013;13:1047
   PubMed Web of Science ®Google Scholar